For the twelve months ended Sep 30, 2026, Caris Life Sciences Inc. reported $1.05B of revenue and $96.06M of net income.
CAI revenue was $275.36M in fiscal Q3 2026 (ended Sep 30, 2026), up 27.0% from a year earlier and up 4.4% from the prior quarter. For the full fiscal 2025 it was $812.03M, up 97.0% from fiscal 2024.
CAI net income was $15.25M in fiscal Q3 2026 (ended Sep 30, 2026), down 37.3% from a year earlier. For the full fiscal 2025 it was -$68.09M, compared with -$281.89M in fiscal 2024.
CAI diluted EPS was $0.05 in fiscal Q3 2026 (ended Sep 30, 2026), down 37.5% from a year earlier. For the full fiscal 2025 it was -$3.22.
CAI free cash flow was -$39.72M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $55.33M a year earlier. For the full fiscal 2025 it was $66.89M, compared with -$253.64M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $812.03M | $412.26M | $306.13M |
| Research and development | $101.58M | $113.92M | $116.88M |
| Selling, general and admin | $224.97M | $169.39M | $149.05M |
| Operating income | $45.11M | -$257.12M | -$319.55M |
| Interest expense | $56.85M | $50.02M | $31.61M |
| Pre-tax income | -$68.09M | -$281.89M | -$341.42M |
| Income tax | $0 | $0 | $0 |
| Net income | -$68.09M | -$281.89M | -$341.42M |
| EPS, basic | -$3.22 | -$10.66 | -$13.24 |
| EPS, diluted | -$3.22 | -$10.66 | -$13.24 |
| Diluted shares | 167.2M | 35.5M | 34.9M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $796.27M | $63.95M | - |
| Short-term investments | $2.29M | $2.20M | - |
| Receivables | $112.14M | $88.24M | - |
| Current assets | $997.80M | $215.73M | - |
| Goodwill | $19.34M | $19.34M | - |
| Total assets | $1.13B | $343.73M | - |
| Current liabilities | $127.14M | $165.42M | - |
| Short-term debt | $169.0K | $60.09M | - |
| Long-term debt | $378.82M | $319.44M | - |
| Total debt | $378.99M | $379.53M | - |
| Total liabilities | $548.36M | $620.92M | - |
| Shareholders' equity | $577.31M | -$2.50B | -$2.14B |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $83.16M | -$245.20M | -$276.10M |
| Capital expenditures | $16.26M | $8.44M | $22.32M |
| Free cash flow | $66.89M | -$253.64M | -$298.42M |
| Investing cash flow | -$16.26M | $52.93M | $214.77M |
| Financing cash flow | $664.99M | $200.29M | $10.13M |
| Share repurchases | $113.0K | $0 | $0 |
| Stock-based compensation | $70.01M | $18.64M | $15.24M |
| Depreciation and amortization | $22.61M | $48.91M | $49.00M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $275.36M | $263.71M | $216.17M | $292.89M | $216.83M | $181.40M | $120.92M | $129.91M | $101.62M | $100.05M | $80.68M |
| Research and development | $33.84M | $32.36M | $31.32M | $31.84M | $21.62M | $25.05M | $23.07M | $27.11M | $27.64M | $24.79M | $34.38M |
| Selling, general and admin | $69.28M | $66.55M | $59.71M | $56.51M | $51.97M | $64.37M | $52.12M | $43.11M | $40.85M | $41.07M | $44.35M |
| Operating income | $19.32M | $26.93M | $5.28M | $88.41M | $32.64M | -$17.99M | -$57.95M | -$37.05M | -$60.84M | -$67.01M | -$92.22M |
| Interest expense | $9.25M | $9.23M | $12.81M | $11.36M | $13.51M | $19.21M | $12.78M | $13.26M | $13.80M | $13.67M | $9.29M |
| Pre-tax income | $16.87M | -$614.0K | -$644.0K | $81.96M | $24.32M | -$71.79M | -$102.58M | -$36.95M | -$67.73M | -$66.19M | -$111.03M |
| Income tax | $1.62M | $23.0K | -$134.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $15.25M | -$637.0K | -$510.0K | $81.96M | $24.32M | -$71.79M | -$102.58M | -$36.95M | -$67.73M | -$66.19M | -$111.03M |
| EPS, basic | $0.05 | $0.00 | $0.00 | - | $0.09 | -$7.97 | -$3.57 | - | -$2.59 | -$2.54 | - |
| EPS, diluted | $0.05 | $0.00 | $0.00 | - | $0.08 | -$7.97 | -$3.57 | - | -$2.59 | -$2.54 | - |
| Diluted shares | 295.1M | 282.9M | 282.6M | - | 297.2M | 64.9M | 35.6M | - | 35.6M | 35.4M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | - | - | $819.90M | $796.27M | $753.22M | $718.93M | $31.20M | $63.95M | - | - | - |
| Short-term investments | $102.06M | $102.20M | $2.31M | $2.29M | $2.27M | $2.25M | - | $2.20M | - | - | - |
| Receivables | $133.32M | $116.89M | $90.52M | $112.14M | $26.70M | $50.89M | - | $88.24M | - | - | - |
| Current assets | $1.07B | $1.06B | $1.01B | $997.80M | $854.25M | $833.32M | - | $215.73M | - | - | - |
| Goodwill | $19.34M | $19.34M | $19.34M | $19.34M | $19.34M | $19.34M | - | $19.34M | - | - | - |
| Total assets | $1.26B | $1.23B | $1.16B | $1.13B | $984.57M | $955.06M | - | $343.73M | - | - | - |
| Current liabilities | $158.95M | $191.44M | $143.90M | $127.14M | $86.03M | $90.18M | - | $165.42M | - | - | - |
| Short-term debt | $89.0K | $178.0K | $173.0K | $169.0K | $164.0K | $95.0K | - | $60.09M | - | - | - |
| Long-term debt | $393.18M | $392.97M | $381.40M | $378.82M | $376.30M | $373.61M | - | $319.44M | - | - | - |
| Total debt | $393.27M | $393.15M | $381.57M | $378.99M | $376.46M | $373.71M | - | $379.53M | - | - | - |
| Total liabilities | $616.14M | $637.89M | $568.90M | $548.36M | $506.21M | $502.15M | - | $620.92M | - | - | - |
| Shareholders' equity | $639.48M | $591.73M | $593.49M | $577.31M | $478.36M | $452.90M | -$2.60B | -$2.50B | -$2.44B | -$2.36B | -$2.27B |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.25M | $28.48M | $32.88M | $44.78M | $62.42M | $7.29M | -$31.34M | -$38.92M | -$69.43M | - | - |
| Capital expenditures | $17.47M | $22.07M | $10.34M | $5.09M | $7.09M | $1.39M | $2.69M | $2.29M | $1.83M | - | - |
| Free cash flow | -$39.72M | $6.40M | $22.53M | $39.69M | $55.33M | $5.90M | -$34.03M | -$41.21M | -$71.25M | - | - |
| Investing cash flow | -$17.47M | -$122.19M | -$10.34M | -$5.09M | -$7.09M | -$1.39M | -$2.69M | -$2.29M | -$1.83M | - | - |
| Financing cash flow | $14.23M | -$36.90M | $824.0K | $3.40M | -$21.10M | $681.40M | $1.28M | $226.0K | $87.0K | - | - |
| Share repurchases | $10.01M | $21.36M | $0 | $91.0K | $0 | $0 | $22.0K | $0 | $0 | - | - |
| Stock-based compensation | $18.50M | $22.22M | $15.87M | $13.37M | $13.65M | $28.29M | $14.69M | $4.98M | $4.72M | - | - |
| Depreciation and amortization | $6.60M | $6.50M | $5.07M | $4.29M | $4.90M | $6.40M | $7.04M | $9.07M | $10.50M | $11.60M | $17.71M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 27.0% | 45.4% | 78.8% | 125.4% | 113.4% | 81.3% | 49.9% | - | - | - | - |
| Net income growth, YoY | -37.3% | - | - | - | - | - | - | - | - | - | - |
| EPS growth, YoY | -37.5% | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 7.0% | 10.2% | 2.4% | 30.2% | 15.1% | -9.9% | -47.9% | -28.5% | -59.9% | -67.0% | -114.3% |
| Net margin | 5.5% | -0.2% | -0.2% | 28.0% | 11.2% | -39.6% | -84.8% | -28.4% | -66.6% | -66.2% | -137.6% |
| Free cash flow margin | -14.4% | 2.4% | 10.4% | 13.6% | 25.5% | 3.3% | -28.1% | -31.7% | -70.1% | - | - |
| Current ratio | 6.71 | 5.53 | 7.05 | 7.85 | 9.93 | 9.24 | - | 1.30 | - | - | - |
| Debt to equity | 0.61 | 0.66 | 0.64 | 0.66 | 0.79 | 0.83 | - | - | - | - | - |
Source: XBRL data Caris Life Sciences Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CAI | $1.05B | +61.5% | $96.06M | 9.2% | $7.24B |
| UNH | $449.66B | +3.3% | $15.88B | 3.5% | $353.17B |
| ELV | $201.83B | +3.6% | $5.13B | 2.5% | $91.96B |
| CI | $286.32B | +6.8% | $5.99B | 2.1% | $77.58B |
| HUM | $154.19B | +22.0% | $1.25B | 0.8% | $52.08B |
| NTRA | $2.91B | +37.4% | -$164.71M | -5.7% | $44.78B |
| CNC | $203.90B | +9.7% | $1.46B | 0.7% | $34.53B |
| ILMN | $4.54B | +5.8% | $895.00M | 19.7% | $32.22B |
| LH | $14.59B | +6.0% | $1.00B | 6.9% | $29.77B |